Long lasting disease-modifying therapy in osteoarthritis
BN-02 protects cartilage from degradation
via selective and cartilage-specific inhibition of multiple critical proteases.
Once catabolic processes are reduced, BN-02 triggers an anabolic cascade, leading to restoration of functional cartilage.
Osteoarthritis, a major public health problem with high unmet medical need.
Osteoarthritis (OA) is a degenerative joint disease characterized by progressive breakdown of load bearing articular cartilage and subchondral bone. These structural changes are associated with low-level inflammation and lead to impaired movement, stiffness and pain.
OA is the most common form of arthritis and a major cause of disability and impaired quality of life in older individuals. One out of two adults will develop knee OA during their lives.
Despite the high unmet medical need for an effective disease-modifying treatment, currently only symptom-modifying drugs are available. Patients with established osteoarthritis are still prone to joint replacement. The major hurdle for the development of effective disease-modifying therapy is the complexity of the disease process. This calls for a more comprehensive therapeutic approach, able to interfere with multiple disease driving targets simultaneously.
Through the unique multimodal functionality of BN-02, we aim to change the standard of care in OA by reversing the disease process.